Autopsy report · NCT01805960
Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF
Cause of deathNo reason given
Life of this trial
- Registered 3 months before it started.
- Ran for about 3 years 6 months before it stopped.
- 24 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Conditions
- Atrial Fibrillation
- Interventions
- Canakinumab; Placebo
- Participants
- 24
- Sites
- 5
- Countries
- Germany, Switzerland
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.